Störungen des Mineral- und Knochenhaushalts bei chronischen Nierenkrankheiten

ZUSAMMENFASSUNG

Im Jahr 2017 wurde das letzte Update der Leitlinien zu den Störungen des Mineral- und Knochenhaushalts bei chronischen Nierenkrankheiten (CKD-MBD: „chronic kidney disease – mineral and bone disorders“) der Initiative KDIGO (Kidney Disease: Improving Global Outcomes) publiziert. Seitdem haben sich neue Erkenntnisse zu Themen wie Knochenqualität und -umsatz im Kontext der Osteoporose, dem Umgang mit progressiven Gefäßverkalkungen, der Einschätzung des Vitamin-D-Status und der Regulation des Parathormons (PTH) ergeben. Dieser Übersichtsartikel benennt exemplarisch diese teilweise neuen Einschätzungen und stellt potenzielle Auswirkungen auf zukünftige diagnostische und therapeutische Verfahrensweisen dar.

Publikationsverlauf

Artikel online veröffentlicht:
12. Dezember 2024

• Literatur

• 1 Dachverband Osteologie e. V. (DVO). DVO Leitlinie Osteoporose 2023 (10.09.2023). Im Internet:. https://leitlinien.dv-osteologie.org/ Stand: 17.09.2024
• 2 Moe S, Drüeke T, Cunningham J. et al Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953
• 3 Jørgensen HS, Lloret MJ, Lalayiannis AD. et al Ten tips on how to assess bone health in patients with chronic kidney disease. Clin Kidney J 2024; 17: sfae093
• 4 Evenepoel P, Claes K, Meijers B. et al Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients. Kidney Int 2019; 95: 1461-1470
• 5 Ketteler M, Block GA, Evenepoel P. et al Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int 2017; 92: 26-36
• 6 Desbiens LC, Sidibé A, Beaudoin C. et al Comparison of fracture prediction tools in individuals without and with early chronic kidney disease: a population-based analysis of CARTaGENE. J Bone Miner Res 2020; 35: 1048-1057
• 7 Germain MJ, Paul SK, Fadda G. et al Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients. BMC Nephrol 2022; 23: 362
• 8 Jahnen-Dechent W, Pasch A. Solving the insoluble: calciprotein particles mediate bulk mineral transport. Kidney Int 2023; 103: 663-665
• 9 Wald R, Thorpe KE, Walsh MW. Leveraging pragmatic clinical trial design to advance phosphate management in end-stage renal disease. Curr Opin Nephrol Hypertens 2019; 28: 34-39
• 10 Hanudel MR, Laster ML, Portale AA. et al A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial. Pediatr Nephrol 2022; 37: 2547-2557
• 11 Ross AC, Taylor CL, Yaktine AL, Del Valle HB. eds. Institute of Medicine Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Washington (DC): National Academies Press (US); 2011.
• 12 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on dietary reference values for calcium. EFSA Journal 2015; 13: 4101
• 13 Evenepoel P, Jørgensen HS, Bover J. et al Recommended calcium intake in adults and children with chronic kidney disease – a European consensus statement. Nephrol Dial Transplant 2024; 39: 341-366
• 14 Yamaguchi S, Hamano T, Doi Y. et al Hidden hypocalcemia as a risk factor for cardiovascular events and all-cause mortality among patients undergoing incident hemodialysis. Sci Rep 2020; 10: 4418
• 15 Shroff R, Lalayiannis AD, Fewtrell M. et al Naturally occurring stable calcium isotope ratios are a novel biomarker of bone calcium balance in chronic kidney disease. Kidney Int 2022; 102: 613-623
• 16 Saritas T, Reinartz S, Krüger T. et al Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: the VitaVasK randomized controlled trial. Clin Kidney J 2022; 15: 2300-2311
• 17 Kaesler N, Schreibing F, Speer T. et al Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease. Kidney Int 2022; 101: 338-348
• 18 Wen W, Portales-Castillo I, Seethapathy R. et al Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients – a systematic review and meta-analysis. Nephrol Dial Transplant 2023; 38: 733-745
• 19 Adirekkiat S, Sumethkul V, Ingsathit A. et al Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 1923-1929
• 20 Sakaguchi Y, Hamano T, Obi Y. et al A randomized trial of magnesium oxide and oral carbon adsorbent for coronary artery calcification in predialysis CKD. J Am Soc Nephrol 2019; 30: 1073-1085
• 21 Bressendorff I, Hansen D, Schou M. et al The effect of magnesium supplementation on vascular calcification in CKD: a randomized clinical trial (MAGiCAL-CKD). J Am Soc Nephrol 2023; 34: 886-894
• 22 Raggi P, Bellasi A, Bushinsky D. et al Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: results of a randomized phase 2b study. Circulation 2020; 141: 728-739
• 23 Sinha S, Nigwekar SU, Brandenburg V. et al Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension. EClinicalMedicine 2024; 75: 102784